Work

TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps8668

Authors: Giuseppe Lo Russo, Margarita Majem, Kenneth John O'Byrne, Thorsten Oliver Goetze, Christian Mueller, Frederic Triebel

Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital de Sant Pau, Translational Research Institute, Queensland University of Technology, Princess Alexandra Hospital, Institute of Clinical Cancer Research, Krankenhaus Nordwest, Immutep (Germany)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410804724

FWCI: 0.366

Cites:

Cited by: 1

Related to: 10